Latest News

Adobe's business is holding solid despite AI challenges.

Apple has been a solid performer this year, but not all of its performance is rooted in business success.

Investors should be ready to buy, not sell, when turbulence intensifies.

AFFO grew 10.5% year-over-year as acquisitions and development funding accelerated cash income.

Advisory revenues surged 18% as energy group deals doubled on AI data center demand.

Amgen can appeal to various kinds of investors.

Disney rose 6% in October, and there are catalysts in the month ahead to keep the gains coming.

Gross margins recovered sharply as Jinko shifted to high-efficiency modules and storage.

Fleet expansion drove 44% revenue growth as new vessels entered service.

When the switch flipped for Tesla and its Model 3 production breakthrough, financial success quickly followed. Rivian could be approaching a similar moment in its young history, and here's what it could look like.

AI voice adoption sits below 1% penetration, leaving Twilio years of runway to expand margins and convert single-product customers into platform users.

Agricultural sales fell 11.7% amid weak demand; 2026 may mark floor.

Casualty lines surge 146% as Hippo raises full-year guidance on improved underwriting.

Michael Kors and Jimmy Choo improved sequentially; management raised full-year guidance.

Wholesale order momentum for spring 2027 suggests the company's turnaround strategy is taking hold beyond its core e-commerce push.

Organic sales beat guidance at 5.1% as volume gains offset inflation.

Be cautious before rushing into pure-play quantum computing.

Does the flash memory company look like the split stocks that kept climbing?

Roblox is importing external games and monetizing older players, two structural shifts that reshape its competitive position.

Net interest income grew fourth consecutive quarter amid CRE headwinds.

Production beat guidance by 4% while net debt fell 20% on strong cash generation.

Ahead of its IPO, investors must weigh the AI lab's improving operating results against its enormous spending commitments.

Management is choosing financial discipline over growth and betting that debt reduction will prove more valuable than new capacity in an uncertain cycle.

GLP-1 weight loss drugs are propelling profits for some drugmakers like Eli Lilly.

Margin expansion and automation gains are outpacing revenue headwinds, signaling how operational leverage can drive long-term compounding.